Repaglinide: prandial glucose regulation in clinical practice

doi:10.1046/j.1463-1326.2000.0022s.x

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Systems Maintenance, Monday, 15th February 2010

Wiley InterScience

Diabetes, Obesity and Metabolism

Volume 2 Issue s1, Pages S43 - S48

Published Online: 4 Jan 2002

< Previous Abstract | Next Abstract >

Save Article to My Profile Download Citation Request Permissions

Abstract | References | Full Text: HTML, PDF (Size: 71K) | Related Articles | Citation Tracking

Repaglinide: prandial glucose regulation in clinical practice

David R. Owens ¹ and Alan McDougall ²

1 Diabetes Research Unit, Llandough Hospital, Penarth, South Glamorgan, UK 2 Novo Nordisk Pharmaceuticals Ltd, Crawley, West Sussex, UK

Correspondence:
Professor David R. Owens, Diabetes Research Unit, Department of Medicine, 1st Floor, Academic Centre, Llandough Hospital, Penlan Road, Penarth, South Glamorgan, CF64 2XX, UK.
E-mail:
owensdr@cf.ac.uk

KEYWORDS

type 2 diabetes • glycaemic control • prandial glucose regulation • repaglinide • monotherapy • combination therapy • efficacy • safety